• Je něco špatně v tomto záznamu ?

Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study

N. Cooper, AJG. Jansen, R. Bird, J. Mayer, M. Sholzberg, MD. Tarantino, M. Garg, PF. Ypma, V. McDonald, C. Percy, M. Košťál, I. Goncalves, LH. Bogdanov, TB. Gernsheimer, R. Diab, M. Yao, A. Daak, DJ. Kuter

. 2025 ; 100 (3) : 439-449. [pub] 20250122

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, klinické zkoušky, fáze II, multicentrická studie, klinické zkoušky, fáze I

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009671

Grantová podpora
Sanofi

Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count < 30 × 109/L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017-004012-19). Oral rilzabrutinib 400 mg bid was given over 24 weeks, with optional long-term extension (LTE). Primary endpoints were safety and platelet counts ≥ 50 × 109/L on ≥ 8 of the last 12 weeks of main treatment without rescue medication. From 22 March2018 to 31 January2023, 26 patients were enrolled. Patients had baseline median platelet count 13 × 109/L, ITP duration 10.3 years, and six prior ITP therapies (46% splenectomized). Nine (35%) patients achieved the primary endpoint. Platelet counts ≥ 50 × 109/L or ≥ 30 × 109/L and doubling from baseline without rescue therapy were sustained for a mean 9.3 weeks. 11 (42%) LTE-eligible patients were ongoing with median LTE platelet > 80 × 109/L. Three (12%) patients received rescue medication during main treatment, none in LTE. Clinically meaningful improvements were observed in fatigue and women's health. With a median treatment duration of 167 days (main treatment), 16 (62%) patients had ≥ 1 treatment-related adverse event (AE), mainly grade 1, including diarrhea (35%), headache (23%), and nausea (15%). There was no treatment-related grade ≥ 2 bleeding/thrombotic events/infections, serious AE, or death. Rilzabrutinib continues to demonstrate durable platelet responses with favorable safety profile in previously treated ITP patients. Trial Registration: NCT03395210, EudraCT 2017-004012-19.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009671
003      
CZ-PrNML
005      
20250429134456.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.27539 $2 doi
035    __
$a (PubMed)39844469
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cooper, Nichola $u Department Immunology and Inflammation, Imperial College, Hammersmith Hospital, London, UK $1 https://orcid.org/0000000298458292
245    10
$a Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study / $c N. Cooper, AJG. Jansen, R. Bird, J. Mayer, M. Sholzberg, MD. Tarantino, M. Garg, PF. Ypma, V. McDonald, C. Percy, M. Košťál, I. Goncalves, LH. Bogdanov, TB. Gernsheimer, R. Diab, M. Yao, A. Daak, DJ. Kuter
520    9_
$a Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count < 30 × 109/L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017-004012-19). Oral rilzabrutinib 400 mg bid was given over 24 weeks, with optional long-term extension (LTE). Primary endpoints were safety and platelet counts ≥ 50 × 109/L on ≥ 8 of the last 12 weeks of main treatment without rescue medication. From 22 March2018 to 31 January2023, 26 patients were enrolled. Patients had baseline median platelet count 13 × 109/L, ITP duration 10.3 years, and six prior ITP therapies (46% splenectomized). Nine (35%) patients achieved the primary endpoint. Platelet counts ≥ 50 × 109/L or ≥ 30 × 109/L and doubling from baseline without rescue therapy were sustained for a mean 9.3 weeks. 11 (42%) LTE-eligible patients were ongoing with median LTE platelet > 80 × 109/L. Three (12%) patients received rescue medication during main treatment, none in LTE. Clinically meaningful improvements were observed in fatigue and women's health. With a median treatment duration of 167 days (main treatment), 16 (62%) patients had ≥ 1 treatment-related adverse event (AE), mainly grade 1, including diarrhea (35%), headache (23%), and nausea (15%). There was no treatment-related grade ≥ 2 bleeding/thrombotic events/infections, serious AE, or death. Rilzabrutinib continues to demonstrate durable platelet responses with favorable safety profile in previously treated ITP patients. Trial Registration: NCT03395210, EudraCT 2017-004012-19.
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a idiopatická trombocytopenická purpura $x farmakoterapie $7 D016553
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    12
$a proteinkinasa BTK $x antagonisté a inhibitory $7 D000077329
650    12
$a inhibitory proteinkinas $x škodlivé účinky $x terapeutické užití $x aplikace a dávkování $7 D047428
650    _2
$a počet trombocytů $7 D010976
650    _2
$a aplikace orální $7 D000284
650    _2
$a pyrimidiny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011743
650    _2
$a výsledek terapie $7 D016896
650    _2
$a pyrazoly $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D011720
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory tyrosinkinasy $7 D000092004
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze I $7 D017426
700    1_
$a Jansen, A J Gerard $u Erasmus MC, University Medical Center, Rotterdam, The Netherlands $1 https://orcid.org/0000000226121420
700    1_
$a Bird, Robert $u Princess Alexandra Hospital, Woolloongabba, Australia $1 https://orcid.org/0000000231101424
700    1_
$a Mayer, Jiří $u Masaryk University Hospital, Brno, Czech Republic $1 https://orcid.org/0000000305679887 $7 nlk20000083651
700    1_
$a Sholzberg, Michelle $u St. Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ontario, Canada $1 https://orcid.org/0000000312200301
700    1_
$a Tarantino, Michael D $u The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, Illinois, USA $1 https://orcid.org/0000000200698176
700    1_
$a Garg, Mamta $u Leicester Royal Infirmary, Leicester, UK $1 https://orcid.org/0000000235600132
700    1_
$a Ypma, Paula F $u Department of Hematology, HagaZiekenhuis, Den Haag, The Netherlands $1 https://orcid.org/0000000312507979
700    1_
$a McDonald, Vickie $u Barts Health NHS Trust, The Royal London Hospital, London, UK $1 https://orcid.org/0000000343928223
700    1_
$a Percy, Charles $u Queen Elizabeth Hospital, Birmingham, UK
700    1_
$a Košťál, Milan $u Fourth Department of Internal Medicine and Hematology, Faculty of Medicine, University Hospital of Hradec Králové, Hradec Králové, Czech Republic $1 https://orcid.org/0000000206865852
700    1_
$a Goncalves, Isaac $u Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Australia
700    1_
$a Bogdanov, Lachezar H $u Clinic of Hematology, University Hospital, Pleven, Bulgaria
700    1_
$a Gernsheimer, Terry B $u University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA $1 https://orcid.org/0000000226715608
700    1_
$a Diab, Remco $u Sanofi, Rotkreuz, Zug, Switzerland $1 https://orcid.org/0009000666608571
700    1_
$a Yao, Mengjie $u Sanofi, Bridgewater, New Jersey, USA
700    1_
$a Daak, Ahmed $u Sanofi, Cambridge, Massachusetts, USA $1 https://orcid.org/0000000221226813
700    1_
$a Kuter, David J $u Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA $1 https://orcid.org/0000000320848810
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 100, č. 3 (2025), s. 439-449
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39844469 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134452 $b ABA008
999    __
$a ok $b bmc $g 2311191 $s 1246752
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 100 $c 3 $d 439-449 $e 20250122 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
GRA    __
$p Sanofi
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace